Skip to main content
Clinical Trials/EUCTR2016-000431-40-FR
EUCTR2016-000431-40-FR
Active, not recruiting
Phase 1

Randomized controlled study evaluating the effect of a biotherapy treatment (anti-RANKL ligand antibody: Denosumab) on bone and vascular metabolism in osteoporotic chronic kidney disease - HDENO

Health Ministry0 sitesJune 17, 2016

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
MedDRA version: 19.0Level: LLTClassification code 10009119Term: Chronic renal failureSystem Organ Class: 100000004857
Sponsor
Health Ministry
Status
Active, not recruiting
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 17, 2016
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
Health Ministry

Eligibility Criteria

Inclusion Criteria

  • Patient female of 65 years or older
  • Chronic kidney disease stage 5 patient, hemodialyzed with extracorporeal treatment for at least 3 months
  • History of vertebral fracture
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range 0
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 30

Exclusion Criteria

  • Cinacalcet treatment
  • Substitutive hormonal treatment
  • Calcium phosphate balance (PTH, 25(OH) vitamin D3, Calcium, phosphate) outside the KDIGO guidelines
  • Hypersensibility to active substance or one of excipients of Prolia®

Outcomes

Primary Outcomes

Not specified

Similar Trials